Nuvalent, Inc.
corporate_fare Company Profile
Nuvalent, Inc. (NASDAQ:NUVL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for NUVL at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Nuvalent Submits New Drug Application for Neladalkib in ALK-Positive NSCLC
- Nuvalent Files Annual Report, Highlights Zidesamtinib NDA with September 2026 PDUFA Date and Extended Cash Runway into 2029
- Nuvalent Reports Strong Q4/FY25 Results, Secures Zidesamtinib PDUFA Date, and Plans Neladalkib NDA
- Nuvalent Reports $1.4B Cash, Extends Runway to 2029, and Advances Key Oncology NDAs Towards 2026 Milestones
Financial Snapshot
Fiscal year ended December 31, 2025
Net Income
-$425.38M
Diluted EPS
-$5.85
Op. Cash Flow
-$275.21M
Operating Income
-$414.31M
Cash & Equivalents
$261.75M
Debt / Equity
0.00×
Shares Outstanding
72.69M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-073317